Guardant Health signaled aggressive expansion of its screening business and disclosed the acquisition of early cancer detection startup MetaSight Diagnostics for $59 million upfront plus up to $90 million in milestones. The company reiterated guidance calling for substantial scaling of its Shield colorectal screening volumes and revenue in 2026, driven by partnerships and commercial roll‑out plans with large lab networks. Shield is an FDA‑approved blood test for colorectal cancer screening that integrates genomic, epigenomic and proteomic signals; Guardant expects sequential quarterly volume gains and wider provider adoption this year.